Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

DPP-IVi, SGLT2i

February 05, 2020

Merck Keeps Januvia As it Spins Off Other Legacy Brands

Here is a brief preview of this blast: In conjunction with Merck's Q4 and FY 2019 earnings call, the company announced plans to create a spin-off company with assets from Merck's Women's Health, Legacy Brands, and Biosimilars business. There was no mention of Merck/Pfizer's Steglatro franchise on the call. Below, FENIX provides highlights from the Merck earnings call as well as insights as to why Januvia is not included in the spinoff company.